Barriers to COVID-19 Health Products in Low-and Middle-Income Countries During the COVID-19 Pandemic: A Rapid Systematic Review and Evidence Synthesis

Abstract

IntroductionThe coronavirus disease 2019 (COVID-19) pandemic has intensified the urgency in addressing pressing global health access challenges and has also laid bare the pervasive structural and systemic inequities that make certain segments of society more vulnerable to the tragic consequences of the disease. This rapid systematic review analyses the barriers to COVID-19 health products in low-and middle-income countries (LMICs). It does so from the canon of global health equity and access to medicines by proposing an access to health products in low-and middle-income countries framework and typology adapted to underscore the complex interactive and multiplicative nature and effects of barriers to health products and their root cause as they coexist across different levels of society in LMICs.MethodsModified versions of the Joanna Briggs Institute (JBI) reviewers' manual for evidence synthesis of systematic reviews and the PRISMA-ScR framework were used to guide the search strategy, identification, and screening of biomedical, social science, and gray literature published in English between 1 January 2020 and 30 April 2021.ResultsThe initial search resulted in 5,956 articles, with 72 articles included in this review after screening protocol and inclusion criteria were applied. Thirty one percent of the articles focused on Africa. The review revealed that barriers to COVID-19 health products were commonly caused by market forces (64%), the unavailability (53%), inaccessibility (42%), and unaffordability (35%), of the products, incongruent donors' agenda and funding (33%) and unreliable health and supply systems (28%). They commonly existed at the international and regional (79%), health sectoral (46%), and national cross-sectoral [public policy] (19%) levels. The historical heritage of colonialism in LMICs was a commonly attributed root cause of the barriers to COVID-19 health products in developing countries.ConclusionThis review has outlined and elaborated on the various barriers to health products that must be comprehensively addressed to mount a successful global, regional, national and subnational response to present and future epidemics and pandemics in LMICs.

A multi-country survey on access to healthcare and treatment services among individuals with critical medical care needs during the first wave of the pandemic

“…Finally, our study findings suggest that the country of residence may be a moderating factor for access to health care, medications and access to alternative medical care services. We observed that people who reside in LICs may not only had challenges accessing healthcare and obtaining medications [51,52] but also seem more likely not be able to use alternative medical care services. Though people in HICs had challenges with accessibility to healthcare services during the COVID-19 pandemic [32] the study results indicates that they had less challenges with access to healthcare when compared with LICs and UMICs; obtaining medications when compared with LICs, LMICs and UMICs; and use of alternative medical care when compared with LICs and LMICs during the first wave of the COVID-19 pandemic.…”

Host DNA depletion can increase the sensitivity of Mycobacterium spp. detection through shotgun metagenomics in sputum

“…The sample composition affected the number of M. tuberculosis reads and depended on the amount of human and bacterial DNA in the sample ( Votintseva et al, 2017 ). Although, the use of certain commercial extraction kits can reduce the turnaround time and are easier to standardize and validate ( Votintseva et al, 2017 ), they are usually more costly and might not be suitable for low- and middle-income settings where there is unavailability or inaccessibility of certain kits/reagents ( Boro and Stoll, 2022 ).…”

“…These results suggest that saponin followed by DNase I treatment depletes Gram-negative bacteria. Saponin treatment combined with a DNase I step is an efficient option to deplete host DNA ( Bachmann et al, 2018 ; Charalampous et al, 2019 ; Boro and Stoll, 2022 ), however, the effect on different bacterial species varies depending on the study. In a study optimizing culture-independent genome sequencing, saponin treatment resulted in almost undetectable levels of human DNA with minimal loss of Bordetella pertussis DNA ( Fong et al, 2020 ).…”

Detection of SARS-CoV-2 in saliva by a low-cost LSPR-based sensor

“…12 One of the causes for this disparity of numbers is the lack of reagents and equipment due either to the lack of affordability or to supply chain disruptions. 13 Reverse transcription polymerase chain reaction (RT-PCR) assays were the gold-standard for SARS-CoV-2 testing but require trained staff and sophisticated laboratory facilities. Lateral ow assays (LFAs) have been developed as a rapid mass screening alternative.…”